Progress in the application of molecular biomarkers in gliomas

Biochemical and Biophysical Research Communications

Volumn 465, Issue 1, 2015, Pages 1-4

  Wang, Jing ^a,b   Su, Hong Kai ^a   Zhao, Hua Fu ^b   Chen, Zhong Ping ^a   To, Shing Shun Tony ^b  

^a SUN YAT SEN UNIVERSITY   (China)

^b HONG KONG POLYTECHNIC UNIVERSITY   (Hong Kong)

Author keywords

Biomarkers; Glioblastoma; Glioma; Predictive; Prognosis

Indexed keywords

BIOLOGICAL MARKER; ISOCITRATE DEHYDROGENASE 1; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MOLECULAR MARKER; UNTRANSLATED RNA; DNA LIGASE; DNA METHYLTRANSFERASE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR VIII; IDH1 PROTEIN, HUMAN; ISOCITRATE DEHYDROGENASE; MGMT PROTEIN, HUMAN; TUMOR MARKER; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; CANCER PROGNOSIS; CHROMOSOME 1; CHROMOSOME1P19Q; DNA METHYLATION; GENETIC TRAIT; GLIOMA; HUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; QUALITY OF LIFE; BRAIN NEOPLASMS; CHROMOSOME DELETION; CLASSIFICATION; GENE EXPRESSION; GENETICS; PATHOLOGY; PERSONALIZED MEDICINE; PROGNOSIS; PROMOTER REGION;

BIOMARKERS, TUMOR; BRAIN NEOPLASMS; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 1; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; GENE EXPRESSION; GLIOMA; HUMANS; ISOCITRATE DEHYDROGENASE; PRECISION MEDICINE; PROGNOSIS; PROMOTER REGIONS, GENETIC; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR SUPPRESSOR PROTEINS;

EID: 84940439813     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2015.07.148     Document Type: Short Survey

References (50)

1. J.F. de Groot High-grade gliomas Contin. (Minneap Minn) 21 2015 332 344
2. C.X. Wu, G.S. Lin, Z.X. Lin, and et al. Peritumoral edema shown by MRI predicts poor clinical outcome in glioblastoma World J. Surg. Oncol. 13 2015 97
3. R. Stupp, W.P. Mason, M.J. van den Bent, and et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma N. Engl. J. Med. 352 2005 987 996
4. C. Bell, N. Dowson, M. Fay, and et al. Hypoxia imaging in gliomas with F-fluoromisonidazole PET: toward clinical translation Semin. Nucl. Med. 45 2015 136 150
5. H.S. Phillips, S. Kharbanda, R. Chen, and et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis Cancer Cell 9 2006 157 173
6. R.G. Verhaak, K.A. Hoadley, E. Purdom, and et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1 Cancer Cell 17 2010 98 110
7. C.W. Brennan, R.G. Verhaak, A. McKenna, and et al. The somatic genomic landscape of glioblastoma Cell 155 2013 462 477
8. H. Noushmehr, D.J. Weisenberger, K. Diefes, and et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma Cancer Cell 17 2010 510 522
9. T. Ozawa, M. Riester, Y.K. Cheng, and et al. Most human non-GCIMP glioblastoma subtypes evolve from a common proneural-like precursor glioma Cancer Cell 26 2014 288 300
10. S. Turcan, D. Rohle, A. Goenka, and et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype Nature 483 2012 479 483
11. S. Turcan, A.W. Fabius, A. Borodovsky, and et al. Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine Oncotarget 4 2013 1729 1736
12. J. Balss, J. Meyer, W. Mueller, and et al. Analysis of the IDH1 codon 132 mutation in brain tumors Acta Neuropathol. 116 2008 597 602
13. J.L. Izquierdo-Garcia, L.M. Cai, M.M. Chaumeil, and et al. Glioma cells with the IDH1 mutation modulate metabolic fractional flux through pyruvate carboxylase PLoS One 9 2014 e108289
14. M. Esmaeili, B.C. Hamans, A.C. Navis, and et al. IDH1 R132H mutation generates a distinct phospholipid metabolite profile in glioma Cancer Res. 74 2014 4898 4907
15. C.G. Duncan, B.G. Barwick, G. Jin, and et al. A heterozygous IDH1R132H/WT mutation induces genome-wide alterations in DNA methylation Genome Res. 22 2012 2339 2355
16. C.L. Usher, R.E. Handsaker, T. Esko, and et al. Structural forms of the human amylase locus and their relationships to SNPs, haplotypes and obesity Nat. Genet. 47 2015 921 925
17. T. Schumacher, L. Bunse, S. Pusch, and et al. A vaccine targeting mutant IDH1 induces antitumour immunity Nature 512 2014 324 327
18. M.J. Bello, J. Vaquero, J.M. de Campos, and et al. Molecular analysis of chromosome 1 abnormalities in human gliomas reveals frequent loss of 1p in oligodendroglial tumors Int. J. Cancer 57 1994 172 175
19. J. Reifenberger, G. Reifenberger, L. Liu, and et al. Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p Am. J. Pathol. 145 1994 1175 1190
20. W. Wick, C. Hartmann, C. Engel, and et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide J. Clin. Oncol. 27 2009 5874 5880
21. G. Cairncross, M. Wang, E. Shaw, and et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402 J. Clin. Oncol. 31 2013 337 343
22. Z.Y. Zhang, A.K. Chan, H.K. Ng, and et al. Surgically treated incidentally discovered low-grade gliomas are mostly IDH mutated and 1p19q co-deleted with favorable prognosis Int. J. Clin. Exp. Pathol. 7 2014 8627 8636
23. S. Leu, S. von Felten, S. Frank, and et al. IDH/MGMT-driven molecular classification of low-grade glioma is a strong predictor for long-term survival Neuro Oncol. 15 2013 469 479
24. A.S. Berghoff, J.A. Hainfellner, C. Marosi, and et al. Assessing MGMT methylation status and its current impact on treatment in glioblastoma CNS Oncol. 4 2015 47 52
25. P. Mur, A. Rodriguez de Lope, F.J. Diaz-Crespo, and et al. Impact on prognosis of the regional distribution of MGMT methylation with respect to the CpG island methylator phenotype and age in glioma patients J. Neurooncol 122 2015 441 450
26. G. Minniti, M. Salvati, A. Arcella, and et al. Correlation between O6-methylguanine-DNA methyltransferase and survival in elderly patients with glioblastoma treated with radiotherapy plus concomitant and adjuvant temozolomide J. Neurooncol. 102 2011 311 316
27. M.E. Hegi, A.C. Diserens, T. Gorlia, and et al. MGMT gene silencing and benefit from temozolomide in glioblastoma N. Engl. J. Med. 352 2005 997 1003
28. A. Malmstrom, B.H. Gronberg, C. Marosi, and et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial Lancet Oncol. 13 2012 916 926
29. W. Wick, M. Platten, C. Meisner, and et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial Lancet Oncol. 13 2012 707 715
30. C.E. Pelloski, K.V. Ballman, A.F. Furth, and et al. Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma J. Clin. Oncol. 25 2007 2288 2294
31. M. Cominelli, S. Grisanti, S. Mazzoleni, and et al. EGFR amplified and overexpressing glioblastomas and association with better response to adjuvant metronomic temozolomide J. Natl. Cancer Inst. 107 2015
32. J. Li, Z.J. Taich, A. Goyal, and et al. Epigenetic suppression of EGFR signaling in G-CIMP+ glioblastomas Oncotarget 5 2014 7342 7356
33. S.A. Greenall, J.F. Donoghue, M. Van Sinderen, and et al. EGFRvIII-mediated transactivation of receptor tyrosine kinases in glioma: mechanism and therapeutic implications Oncogene 2015 (Epub ahead of print)
34. D. Annibali, J.R. Whitfield, E. Favuzzi, and et al. Myc inhibition is effective against glioma and reveals a role for Myc in proficient mitosis Nat. Commun. 5 2014 4632
35. H. Zheng, H. Ying, H. Yan, and et al. Pten and p53 converge on c-Myc to control differentiation, self-renewal, and transformation of normal and neoplastic stem cells in glioblastoma Cold Spring Harb. Symp. Quant. Biol. 73 2008 427 437
36. G. Wu, A.K. Diaz, B.S. Paugh, and et al. The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma Nat. Genet. 46 2014 444 450
37. P. Buczkowicz, C. Hoeman, P. Rakopoulos, and et al. Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations Nat. Genet. 46 2014 451 456
38. A.M. Fontebasso, S. Papillon-Cavanagh, J. Schwartzentruber, and et al. Recurrent somatic mutations in ACVR1 in pediatric midline high-grade astrocytoma Nat. Genet. 46 2014 462 466
39. L. Zhang, L.H. Chen, H. Wan, and et al. Exome sequencing identifies somatic gain-of-function PPM1D mutations in brainstem gliomas Nat. Genet. 46 2014 726 730
40. D.J. Brat, R.G. Verhaak, K.D. Aldape, and et al. Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas N. Engl. J. Med. 372 2015 2481 2498
41. H. Suzuki, K. Aoki, K. Chiba, and et al. Mutational landscape and clonal architecture in grade II and III gliomas Nat. Genet. 47 2015 458 468
42. J.E. Eckel-Passow, D.H. Lachance, A.M. Molinaro, and et al. Glioma Groups Based on 1p/19q, IDH, and TERT promoter mutations in tumors N. Engl. J. Med. 372 2015 2499 2508
43. S. Jahr, H. Hentze, S. Englisch, and et al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells Cancer Res. 61 2001 1659 1665
44. H. Schwarzenbach, D.S. Hoon, and K. Pantel Cell-free nucleic acids as biomarkers in cancer patients Nat. Rev. Cancer 11 2011 426 437
45. S.J. Dawson, D.W. Tsui, M. Murtaza, and et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer N. Engl. J. Med. 368 2013 1199 1209
46. M. Murtaza, S.J. Dawson, D.W. Tsui, and et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA Nature 497 2013 108 112
47. B. Boisselier, J. Gallego Perez-Larraya, M. Rossetto, and et al. Detection of IDH1 mutation in the plasma of patients with glioma Neurology 79 2012 1693 1698
48. T. Wakabayashi, A. Natsume, H. Hatano, and et al. p16 promoter methylation in the serum as a basis for the molecular diagnosis of gliomas Neurosurgery 64 2009 455 461 discussion 461-452
49. C. Balana, J.L. Ramirez, M. Taron, and et al. O6-methyl-guanine-DNA methyltransferase methylation in serum and tumor DNA predicts response to 1,3-bis(2-chloroethyl)-1-nitrosourea but not to temozolamide plus cisplatin in glioblastoma multiforme Clin. Cancer Res. 9 2003 1461 1468
50. I. Lavon, M. Refael, B. Zelikovitch, and et al. Serum DNA can define tumor-specific genetic and epigenetic markers in gliomas of various grades Neuro Oncol. 12 2010 173 180